Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma.

by Xiaoqi Xie, Eileen P White, Janice M Mehnert
Published 2013-01-01

Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer

by Janice M Mehnert, Shang-Jui Wang, Karishma Khullar, Sinae Kim, Nikhil Yegya-Raman, Samuel H Crayton, John L Nosher, Michael A Gentile, Salma K Jabbour
Published 2020-07-01

Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanomaResearch in context

by Robert H.I. Andtbacka, Thomas Amatruda, John Nemunaitis, Jonathan S. Zager, John Walker, Jason A. Chesney, Kate Liu, Cheng-Pang Hsu, Cheryl A. Pickett, Janice M. Mehnert
Published 2019-09-01

Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial

by Janice M Mehnert, Isaac Brownell, Sandra P D'Angelo, Kent C Shih, Karl D Lewis, Gerald P Linette, Sara Georges, Parantu Shah, Barbara Ellers-Lenz, Gülseren Güzel, Paul T Nghiem
Published 2020-06-01

Correction: Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report

by Janice M Mehnert, Isaac Brownell, Sandra P D'Angelo, Kent C Shih, Karl D Lewis, Gerald P Linette, Sara Georges, Parantu Shah, Barbara Ellers-Lenz, Gülseren Güzel, Paul T Nghiem
Published 2020-06-01

Correction: A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer

by Janice M Mehnert, Isaac Brownell, Sandra P D'Angelo, Kent C Shih, Karl D Lewis, Gerald P Linette, Sara Georges, Parantu Shah, Barbara Ellers-Lenz, Gülseren Güzel, Paul T Nghiem
Published 2020-06-01

Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial

by Ulrich Keilholz, Janice M. Mehnert, Sebastian Bauer, Hugues Bourgeois, Manish R. Patel, Donald Gravenor, John J. Nemunaitis, Matthew H. Taylor, Lucjan Wyrwicz, Keun-Wook Lee, Vijay Kasturi, Kevin Chin, Anja von Heydebreck, James L. Gulley
Published 2019-01-01

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer

by Janice M. Mehnert, Andrea Varga, Marcia S. Brose, Rahul R. Aggarwal, Chia-Chi Lin, Amy Prawira, Filippo de Braud, Kenji Tamura, Toshihiko Doi, Sarina A. Piha-Paul, Jill Gilbert, Sanatan Saraf, Pradeep Thanigaimani, Jonathan D. Cheng, Bhumsuk Keam
Published 2019-03-01

A multicenter characterization of hepatitis associated with immune checkpoint inhibitors

by J. Randall Patrinely, Ben McGuigan, Sunandana Chandra, Sarah E. Fenton, Akansha Chowdhary, Lucy B. Kennedy, Meghan J. Mooradian, Marisa Palmeri, Daniella Portal, Sara N. Horst, Elizabeth A. Scoville, Georgina V. Long, Chanjuan Shi, Janice M. Mehnert, Ryan J. Sullivan, April K. Salama, Jeffrey A. Sosman, Alexander M. Menzies, Douglas B. Johnson
Published 2021-01-01

Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November–2 December, 2017, Naples, Italy)

by Paolo A. Ascierto, Igor Puzanov, Sanjiv S. Agarwala, Carlo Bifulco, Gerardo Botti, Corrado Caracò, Gennaro Ciliberto, Michael A. Davies, Reinhard Dummer, Soldano Ferrone, Thomas F. Gajewski, Claus Garbe, Jason J. Luke, Francesco M. Marincola, Giuseppe Masucci, Janice M. Mehnert, Nicola Mozzillo, Giuseppe Palmieri, Michael A. Postow, Stephen P. Schoenberger, Ena Wang, Magdalena Thurin
Published 2018-07-01

High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma

by Ann W. Silk, Ann W. Silk, Howard L. Kaufman, Howard L. Kaufman, Howard L. Kaufman, Brendan Curti, Janice M. Mehnert, Kim Margolin, David McDermott, Joseph Clark, Jenna Newman, Praveen K. Bommareddy, Praveen K. Bommareddy, Lisa Denzin, Lisa Denzin, Lisa Denzin, Saltanat Najmi, Saltanat Najmi, Azra Haider, Azra Haider, Weichung Shih, Michael P. Kane, Andrew Zloza, Andrew Zloza
Published 2020-01-01

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0

by Ryan J. Sullivan, Michael B. Atkins, John M. Kirkwood, Sanjiv S. Agarwala, Joseph I. Clark, Marc S. Ernstoff, Leslie Fecher, Thomas F. Gajewski, Brian Gastman, David H. Lawson, Jose Lutzky, David F. McDermott, Kim A. Margolin, Janice M. Mehnert, Anna C. Pavlick, Jon M. Richards, Krista M. Rubin, William Sharfman, Steven Silverstein, Craig L. Slingluff, Vernon K. Sondak, Ahmad A. Tarhini, John A. Thompson, Walter J. Urba, Richard L. White, Eric D. Whitman, F. Stephen Hodi, Howard L. Kaufman
Published 2018-05-01

Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration

by Mark N. Stein, Jyoti Malhotra, Rohinton S. Tarapore, Usha Malhotra, Ann W. Silk, Nancy Chan, Lorna Rodriguez, Joseph Aisner, Robert D. Aiken, Tina Mayer, Bruce G. Haffty, Jenna H. Newman, Salvatore M. Aspromonte, Praveen K. Bommareddy, Ricardo Estupinian, Charles B. Chesson, Evita T. Sadimin, Shengguo Li, Daniel J. Medina, Tracie Saunders, Melissa Frankel, Aparna Kareddula, Sherrie Damare, Elayne Wesolowsky, Christian Gabel, Wafik S. El-Deiry, Varun V. Prabhu, Joshua E. Allen, Martin Stogniew, Wolfgang Oster, Joseph R. Bertino, Steven K. Libutti, Janice M. Mehnert, Andrew Zloza
Published 2019-05-01